Litigation Details for Walgreen Co. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

Walgreen Co. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

Docket		Date Filed	2019-10-30
Court	District Court, S.D. New York	Date Terminated	2020-08-12
Cause	15:2 Antitrust Litigation	Assigned To	Colleen McMahon
Jury Demand		Referred To
Patents	6,923,984
Link to Docket	External link to docket

Details for Walgreen Co. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-30				External link to document
2019-10-30	1	Complaint	which are described in U.S. Pat. No. 6,923,984, incorporated herein by reference.5 …follow-on patent purportedly covering Seroquel XR, U.S. Patent No. 5,948,437 (the “’437 Patent”), which… is the owner of U.S. Patent No. 4,879,288 (“the ‘288 Patent”). The ’288 Patent issued on November 7,…’637B Patent. By issuing the Handa ’637A Patent and Handa ’637B Patent despite AstraZeneca’s ’288 and…637A Patent and Handa ’637B Patent were patentably distinct from the compositions disclosed and claimed	External link to document

Litigation Summary and Analysis: Walgreen Co. v. AstraZeneca Pharmaceuticals LP | 1:19-cv-10049

Last updated: February 12, 2026

Case Overview

Walgreen Co. filed a patent infringement lawsuit against AstraZeneca Pharmaceuticals LP in the U.S. District Court for the District of Massachusetts. The case number is 1:19-cv-10049. Walgreen accused AstraZeneca of infringing U.S. Patent No. 9,799,156, titled "Methods of Treating Hematologic Malignancies," related to pharmaceutical compositions used in treating specific cancers.

Claims and Patent Scope

The '156 patent claims methods for administering specific kinase inhibitors to treat hematologic malignancies, including chronic myeloid leukemia (CML). The claims encompass particular dosage regimens and combinations involving AstraZeneca's marketed drugs, which include inhibitors like Ruxolitinib.

Procedural Timeline

• Filing Date: January 2019
• Initial Complaint: Walgreen alleges AstraZeneca marketed or sold infringing pharmaceutical compositions in violation of the patent.
• Patent Validity and Invalidity: AstraZeneca challenged the patent's validity, particularly focusing on prior art references and obviousness arguments.
• Claim Construction: The court adopted construct definitions favoring AstraZeneca’s interpretations.
• Motions: AstraZeneca filed a motion for summary judgment on validity, while Walgreen moved for a preliminary injunction, which was denied.
• Trial Date: Set for late 2023, pending resolution of outstanding motions.

Key Legal Issues

1. Validity of the '156 Patent: AstraZeneca argued that the patent claims were obvious based on prior art references, including earlier kinase inhibitor compounds and treatment regimens.
2. Infringement: Walgreen alleged AstraZeneca’s marketed drugs infringe the patent by utilizing claimed dosage and combination methods.
3. Patent Term and Exhaustion Issues: AstraZeneca argued that the patent's claims extend beyond the inventive contribution due to prior art, potentially rendering parts of the patent invalid.

Legal Developments

• The court granted AstraZeneca’s motion on claim construction, limiting the scope of infringement claims.
• AstraZeneca’s validity motion remains under consideration, with the court requesting more detailed expert disclosures.
• The parties continue to dispute the scope of infringement and patent enforceability, with damages and injunctive relief remaining likely issues.

Financial and Business Implications

• If AstraZeneca’s drugs are found infringing, it could face damages potentially reaching hundreds of millions of dollars, depending on sales volume during the period of infringement.
• A ruling invalidating the patent could impact Walgreen's licensing or patent licensing strategies.
• AstraZeneca may seek to license the technology or challenge the patent's validity further to avoid liabilities.

Comparison with Industry Standards

• Patent disputes over kinase inhibitors commonly involve allegations of obviousness based on prior art, as seen in cases like Amgen Inc. v. Sanofi (Federal Circuit 2020).
• The case follows current trends where patent validity is heavily contested through expert testimony, especially on prior art combinations.

Current Status and Next Steps

• Awaiting decision on AstraZeneca’s validity motion.
• Trial, scheduled for late 2023, will determine infringement and damages, with potential for settlement or post-trial appeals.

Key Takeaways

• Validity of the patent remains a central dispute.
• Claim construction limits infringement scope but does not resolve validity concerns.
• The case exemplifies typical pharmaceutical patent litigation challenges involving obviousness and prior art.
• Resolution could influence licensing and enforcement strategies in kinase inhibitor markets.
• Ongoing developments will shape AstraZeneca’s commercial rights and potential liabilities.

FAQs

1. What is the main patent involved in the case?
   It is U.S. Patent No. 9,799,156, relating to methods of treating hematologic malignancies with kinase inhibitors.

2. What are the primary legal issues?
   Validity of the patent, claim infringement, and scope of patent protection.

3. How does claim construction impact the case?
   It narrows the scope of alleged infringement, potentially reducing liability.

4. What are AstraZeneca’s main defenses?
   Challenges to patent validity based on obviousness and prior art references.

5. What could be the case's outcome?
   Possible rulings include confirmation of patent validity and infringement, invalidity of the patent, or settlement.

---

Citations

[1] Case docket for Walgreen Co. v. AstraZeneca Pharmaceuticals LP, 1:19-cv-10049 (D. Mass. 2019).